KR20230107628A - Wnt 수용체 ryk에 대한 항체 변이체 - Google Patents
Wnt 수용체 ryk에 대한 항체 변이체 Download PDFInfo
- Publication number
- KR20230107628A KR20230107628A KR1020237019599A KR20237019599A KR20230107628A KR 20230107628 A KR20230107628 A KR 20230107628A KR 1020237019599 A KR1020237019599 A KR 1020237019599A KR 20237019599 A KR20237019599 A KR 20237019599A KR 20230107628 A KR20230107628 A KR 20230107628A
- Authority
- KR
- South Korea
- Prior art keywords
- antibody
- seq
- ryk
- acid sequence
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- G01N33/57484—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063112616P | 2020-11-11 | 2020-11-11 | |
| US63/112,616 | 2020-11-11 | ||
| PCT/US2021/058491 WO2022103705A1 (en) | 2020-11-11 | 2021-11-08 | Antibody variants against wnt receptor ryk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230107628A true KR20230107628A (ko) | 2023-07-17 |
Family
ID=81601681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237019599A Pending KR20230107628A (ko) | 2020-11-11 | 2021-11-08 | Wnt 수용체 ryk에 대한 항체 변이체 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230416375A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4244259A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023552919A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230107628A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117295767A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021380681A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3201419A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202233683A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022103705A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3039910A1 (en) | 2016-03-28 | 2017-10-05 | The Regents Of The University Of California | Anti-ryk antibodies and methods of using the same |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL362324A1 (en) * | 2001-02-19 | 2004-10-18 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| EP2188310B1 (en) * | 2007-08-03 | 2017-02-08 | Genentech, Inc. | Humanized anti-fgf19 antagonists and methods using same |
| US9062101B2 (en) * | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| US9228023B2 (en) * | 2010-10-01 | 2016-01-05 | Oxford Biotherapeutics Ltd. | Anti-ROR1 antibodies and methods of use for treatment of cancer |
| US20130309223A1 (en) * | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| WO2014161037A1 (en) * | 2013-04-03 | 2014-10-09 | Peter Maccallum Cancer Institute | Antibodies against human ryk and uses therefor |
| MA41480A (fr) * | 2014-10-17 | 2017-12-19 | Glenmark Pharmaceuticals Sa | Anticorps qui se lient au ccr6 et leurs utilisations |
| AU2016271111B2 (en) * | 2015-05-29 | 2022-04-28 | Bristol-Myers Squibb Company | Antibodies against OX40 and uses thereof |
| CA3039910A1 (en) * | 2016-03-28 | 2017-10-05 | The Regents Of The University Of California | Anti-ryk antibodies and methods of using the same |
| BR112019017628A2 (pt) * | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
| TWI788340B (zh) * | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| GB201707561D0 (en) * | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
-
2021
- 2021-11-08 CN CN202180089301.4A patent/CN117295767A/zh active Pending
- 2021-11-08 US US18/035,407 patent/US20230416375A1/en active Pending
- 2021-11-08 AU AU2021380681A patent/AU2021380681A1/en active Pending
- 2021-11-08 KR KR1020237019599A patent/KR20230107628A/ko active Pending
- 2021-11-08 JP JP2023552151A patent/JP2023552919A/ja active Pending
- 2021-11-08 EP EP21892641.8A patent/EP4244259A4/en active Pending
- 2021-11-08 WO PCT/US2021/058491 patent/WO2022103705A1/en not_active Ceased
- 2021-11-08 CA CA3201419A patent/CA3201419A1/en active Pending
- 2021-11-11 TW TW110141972A patent/TW202233683A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4244259A4 (en) | 2025-01-15 |
| JP2023552919A (ja) | 2023-12-19 |
| WO2022103705A1 (en) | 2022-05-19 |
| CA3201419A1 (en) | 2022-05-19 |
| US20230416375A1 (en) | 2023-12-28 |
| AU2021380681A9 (en) | 2024-02-08 |
| AU2021380681A1 (en) | 2023-06-15 |
| EP4244259A1 (en) | 2023-09-20 |
| CN117295767A (zh) | 2023-12-26 |
| TW202233683A (zh) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2363622T3 (es) | Moléculas de enlace de lingo y el uso farmacéutico de estas. | |
| TWI770020B (zh) | 人類化抗pacap 抗體及其用途 | |
| TWI729992B (zh) | 用於治療共核蛋白病的藥劑、用途及方法 | |
| JP2024023445A (ja) | 癌の成長を抑制する結合分子 | |
| JP6352812B2 (ja) | 抗cxcr3抗体 | |
| JP5719596B2 (ja) | 抗体及びその誘導体 | |
| CN114133450B (zh) | 抗-Rho GTPase的构象单域抗体及其用途 | |
| BR112020025502A2 (pt) | Anticorpos il-11ra | |
| CN112566940A (zh) | 多特异性wnt替代分子和其用途 | |
| JP2018516361A (ja) | 羞明を処置、予防、または阻害するための抗pacap抗体及びそれらの抗原結合性断片の使用 | |
| KR20210142638A (ko) | Cd3 항원 결합 단편 및 이의 응용 | |
| CN107074937A (zh) | 人源抗亨廷顿蛋白(htt)抗体及其用途 | |
| CA2960466A1 (en) | Cancer cell-specific antibody, anticancer drug and cancer testing method | |
| JP2018516549A (ja) | 結合ポリペプチドを含む細菌を特定する方法 | |
| CN114641310A (zh) | 治疗癌症和其他疾病的靶向α3β1整合素 | |
| TW202000232A (zh) | 用以治療或預防異位性骨化之醫藥組成物 | |
| CN121175410A (zh) | TrkA抗体及其用途 | |
| JP2013542720A (ja) | 抗エフリン−b2抗体およびその使用 | |
| US20230416375A1 (en) | Antibody variants against wnt receptor ryk | |
| TW202337906A (zh) | 抗pilra抗體、其用途以及相關方法及試劑 | |
| KR20230079074A (ko) | 면역글로불린 e 항체 조성물 및 사용 방법 | |
| US20240317867A1 (en) | Igfr-like 2 receptor and uses thereof | |
| HK40115111A (en) | Anti-pilra antibodies, uses thereof, and related methods and reagents | |
| TW202515915A (zh) | 抗pilra抗體、其用途以及相關方法及試劑 | |
| WO2026082710A1 (en) | Small molecule-inducible recombinant receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |